Figure 5.
Treatment and follow‐up scheme. EF, ejection fraction; FDG‐PET, 18‐Fluoro‐2‐deoxyglucose positron emission tomography; LV, left ventricular; RWMA, regional wall motion abnormality
Treatment and follow‐up scheme. EF, ejection fraction; FDG‐PET, 18‐Fluoro‐2‐deoxyglucose positron emission tomography; LV, left ventricular; RWMA, regional wall motion abnormality